Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma

NCT00006011 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT00006011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2000
Completion date
Not reported
Enrollment
659 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, variant with squamous differentiation, endometrial serous adenocarcinoma, stage iii uterine corpus cancer